NAUT - Nautilus Biotech gains on insider buying from CEO

Following a decline of ~8.3% on Wednesday, the shares of Nautilus Biotechnology (NAUT +7.4%) have rebound after the CEO of the life sciences company, Sujal Patel, disclosed the purchase of 250K company shares. According to an SEC filing on Thursday, Patel has executed the transaction early this week, increasing his stake by ~1% to a total value of $1.2M. On Monday, company director Posard Matthew has also acquired 50K shares of Nautilus (NASDAQ:NAUT), raising his stake at the company by ~50% to $225.5K. Early this month, Cowen initiated its coverage of Nautilus (NAUT) with an Outperform recommendation. The analyst Max Masucci predicted the company to reach the commercial stage in 2024. On Wall Street, the stock has garnered two Very Bullish recommendations and one Neutral rating, as shown in the diagram below.

For further details see:

Nautilus Biotech gains on insider buying from CEO